Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

30,000

Participants

Timeline

Start Date

February 21, 2018

Primary Completion Date

October 30, 2024

Study Completion Date

October 30, 2025

Conditions
Typhoid
Interventions
BIOLOGICAL

Vi-Typhoid Conjugate Vaccine (Vi-TCV)

Single 0.5-ml intramuscular injection

BIOLOGICAL

Meningococcal A Conjugate Vaccine (MCV-A)

Single intramuscular injection. Children 9-11 months will receive a 5µg/0.5ml dose. Children 12 months and older will receive a 10µg/0.5 ml dose.

Trial Locations (1)

P.O. Box 30096

Malawi Liverpool Wellcome Trust Clinical Research Programme, Queen Elizabeth Central Hospital College of Medicine, Blantyre

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

collaborator

Malawi-Liverpool-Wellcome Trust Clinical Research Programme

OTHER

collaborator

University College, London

OTHER

collaborator

University of Malawi

OTHER

lead

University of Maryland, Baltimore

OTHER

NCT03299426 - Clinical Efficacy of Typhoid Conjugate Vaccine (Vi-TCV) Among Children Age 9 Months Through 12 Years in Blantyre, Malawi | Biotech Hunter | Biotech Hunter